What do you think?
I really want to know
Extremely short post, but this is worth noting.
This is an important but quite controversial issue. What do you think is going on with these long acting injectables? They are being WIDLY promoted both for ARVs and PrEp.Was this the logical endpoint of the COVID response? My first reaction is that uptake will be abysmal, but I don’t mind being proven wrong.
Retaining people in care forever? MAiD is the logical endpoint.
Looking at injectable drugs, there's a pretty clear economic and social rationale for getting us hooked. This is ChatGPT's answer to "Explain to me why injectable medications are considered lucrative for the healthcare industry" and it matches with research I have done directly.
Injectable medications are considered lucrative for the healthcare industry for several key reasons:
1. Higher Pricing and Reimbursement
Premium pricing: Injectable drugs, especially biologics and specialty medications, are often priced significantly higher than oral medications. This is due to their complex manufacturing processes, clinical value, and the lack of generic competition.
Reimbursement incentives: Many injectables are covered under the medical benefit (rather than the pharmacy benefit), which may allow for markups and provider-administered billing (e.g., “buy and bill” model), especially in outpatient or hospital settings.
2. Patent Protection and Market Exclusivity
Injectable biologics are often protected by longer and more complex patent portfolios, delaying biosimilar competition.
Fewer companies can make biosimilars due to the high cost and regulatory barriers for biologic development, extending the brand’s market dominance.
3. Provider-Administered Revenue
When injections are given in clinical settings (e.g., hospitals, outpatient infusion centers, specialty practices), providers often charge administration fees and can bill for the drug itself at a markup. This creates a revenue stream for hospitals and physicians.
This model incentivizes the use of higher-cost injectables over lower-cost oral alternatives.
4. Chronic Use and Repeat Dosing
Many injectables are used for chronic diseases (e.g., rheumatoid arthritis, multiple sclerosis, certain cancers), requiring regular administration—monthly, weekly, or even more frequently.
This ensures steady, repeat revenue for pharmaceutical companies and the healthcare system.
5. Specialty Pharmacy and Distribution Channels
Injectable drugs are typically distributed through specialty pharmacies or providers, which command high margins and offer services like cold-chain logistics, prior authorization support, and patient monitoring.
These services further embed these drugs into high-value healthcare networks.
I watched David Rasnick commenting about how wrong it is to chronically inject things in people. In this video by Zowe Smith:
https://rumble.com/v6w07k0-turbo-cancer-part-1-debunking-flawed-cancer-theories-with-david-rasnick-phd.html
Around minute 54.
The ARVs and PReP drugs were at one point cancer drugs, right?